376 related articles for article (PubMed ID: 15067328)
1. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas.
Ishizaki Y; Ikeda S; Fujimori M; Shimizu Y; Kurihara T; Itamoto T; Kikuchi A; Okajima M; Asahara T
Int J Oncol; 2004 May; 24(5):1077-83. PubMed ID: 15067328
[TBL] [Abstract][Full Text] [Related]
2. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
[TBL] [Abstract][Full Text] [Related]
3. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
[TBL] [Abstract][Full Text] [Related]
4. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis.
Park JY; Park WS; Nam SW; Kim SY; Lee SH; Yoo NJ; Lee JY; Park CK
Liver Int; 2005 Feb; 25(1):70-6. PubMed ID: 15698401
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
[TBL] [Abstract][Full Text] [Related]
6. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia.
Chen YW; Jeng YM; Yeh SH; Chen PJ
Hepatology; 2002 Oct; 36(4 Pt 1):927-35. PubMed ID: 12297840
[TBL] [Abstract][Full Text] [Related]
7. Abnormalities of the APC/beta-catenin pathway in endometrial cancer.
Moreno-Bueno G; Hardisson D; Sánchez C; Sarrió D; Cassia R; García-Rostán G; Prat J; Guo M; Herman JG; Matías-Guiu X; Esteller M; Palacios J
Oncogene; 2002 Nov; 21(52):7981-90. PubMed ID: 12439748
[TBL] [Abstract][Full Text] [Related]
8. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.
Zucman-Rossi J; Benhamouche S; Godard C; Boyault S; Grimber G; Balabaud C; Cunha AS; Bioulac-Sage P; Perret C
Oncogene; 2007 Feb; 26(5):774-80. PubMed ID: 16964294
[TBL] [Abstract][Full Text] [Related]
10. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
Wei Y; Van Nhieu JT; Prigent S; Srivatanakul P; Tiollais P; Buendia MA
Hepatology; 2002 Sep; 36(3):692-701. PubMed ID: 12198663
[TBL] [Abstract][Full Text] [Related]
11. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway.
Torbenson M; Lee JH; Choti M; Gage W; Abraham SC; Montgomery E; Boitnott J; Wu TT
Mod Pathol; 2002 Mar; 15(3):189-96. PubMed ID: 11904335
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Icat induces G(2) arrest and cell death in tumor cell mutants for adenomatous polyposis coli, beta-catenin, or Axin.
Sekiya T; Nakamura T; Kazuki Y; Oshimura M; Kohu K; Tago K; Ohwada S; Akiyama T
Cancer Res; 2002 Jun; 62(11):3322-6. PubMed ID: 12036951
[TBL] [Abstract][Full Text] [Related]
13. No evidence for involvement of beta-catenin and APC in urothelial carcinomas.
Stoehr R; Krieg RC; Knuechel R; Hofstaedter F; Pilarsky C; Zaak D; Schmitt R; Hartmann A
Int J Oncol; 2002 May; 20(5):905-11. PubMed ID: 11956582
[TBL] [Abstract][Full Text] [Related]
14. The significance of the Wnt pathway in the pathology of human cancers.
Karim R; Tse G; Putti T; Scolyer R; Lee S
Pathology; 2004 Apr; 36(2):120-8. PubMed ID: 15203747
[TBL] [Abstract][Full Text] [Related]
15. Aberrant nuclear localization of beta-catenin without genetic alterations in beta-catenin or Axin genes in esophageal cancer.
Kudo J; Nishiwaki T; Haruki N; Ishiguro H; Shibata Y; Terashita Y; Sugiura H; Shinoda N; Kimura M; Kuwabara Y; Fujii Y
World J Surg Oncol; 2007 Feb; 5():21. PubMed ID: 17309796
[TBL] [Abstract][Full Text] [Related]
16. Correlation between protein expression and epigenetic and mutation changes of Wnt pathway-related genes in oral cancer.
Yeh KT; Chang JG; Lin TH; Wang YF; Chang JY; Shih MC; Lin CC
Int J Oncol; 2003 Oct; 23(4):1001-7. PubMed ID: 12963979
[TBL] [Abstract][Full Text] [Related]
17. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis.
Mao TL; Chu JS; Jeng YM; Lai PL; Hsu HC
J Pathol; 2001 Jan; 193(1):95-101. PubMed ID: 11169521
[TBL] [Abstract][Full Text] [Related]
18. Beta-catenin and cyclin D1 expression in human hepatocellular carcinoma.
Ueta T; Ikeguchi M; Hirooka Y; Kaibara N; Terada T
Oncol Rep; 2002; 9(6):1197-203. PubMed ID: 12375019
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas.
Tokumoto N; Ikeda S; Ishizaki Y; Kurihara T; Ozaki S; Iseki M; Shimizu Y; Itamoto T; Arihiro K; Okajima M; Asahara T
Int J Oncol; 2005 Oct; 27(4):973-80. PubMed ID: 16142313
[TBL] [Abstract][Full Text] [Related]
20. HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing.
Yau TO; Chan CY; Chan KL; Lee MF; Wong CM; Fan ST; Ng IO
Oncogene; 2005 Feb; 24(9):1607-14. PubMed ID: 15580286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
